Development

Articles

Eudratec Fasteric is an oral drug delivery technology that offers enteric protection after rapid, homogeneous release for targeting the upper small intestine.

Evonik Launches New Oral Drug Delivery Technology

The Ventofor Combi Fix will be brought into the Turkish market via Bilim’s development program, while the PowdAir Plus DPI is manufactured and commercialized by H&T Presspart under a patent license from Hovione.

Bilim, H&T Presspart, and Hovione Partner to Bring Asthma Product to the Turkish Market

The new site will offer initial design and development, low-volume manufacturing, and scalable high-quality production of wearable drug delivery devices.

Sorrel to Open a New Manufacturing Facility

Manufacturers and the US government are investing heavily in traditional and non-traditional forms and materials to ensure supplies of containers and delivery devices for COVID-19 treatments and vaccines. 


COVID-19: Shoring Up the Drug Delivery Infrastructure

Inovio received a $71-million contract from the US Department of Defense to scale up manufacture of its Cellectra smart device to deliver its DNA vaccine.

Inovio to Scale-Up Manufacture of Intradermal Delivery Device for its COVID-19 Vaccine

The European Commission has granted marketing authorization to the Janssen Pharmaceutical Companies of Johnson & Johnson for Darzalex (daratumumab) subcutaneous formulation to treat adults with multiple myeloma.

EC Grants Marketing Authorization for Subcutaneous Formulation of Daratumumab

The investment will give the company the opportunity to accelerate the development of proprietary boron-10 target drugs while it develops its neutron beam accelerator technology for Boron Neutron Capture Therapy.

TAE Life Sciences to Launch Drug Delivery Program After $30-Million Investment

Kindeva Drug Delivery plans capital investment and jobs growth.

Former 3M Drug Delivery Systems Launches as Kindeva Drug Delivery

With the acquisition, Orgenesis will combine TamirBio’s ranpirnase antiviral platform with its Bioxome technology.

Orgenesis to Acquire Tamir Biotechnology for Broad Spectrum Antiviral Platform

Industry opportunities are increasing for biosimilars, but companies should pay close attention to delivery device design to facilitate success.


The Design Driver for Biosimilar Adoption

N4 Pharma will be undertaking a proof-of-concept research project using a COVID-19 DNA plasmid to demonstrate the ability of its delivery system, Nuvec, to collaborative partners developing DNA or RNA vaccines.

N4 Pharma Undertakes Research Project Using a COVID-19 DNA Plasmid

As a result of the rising use and development of biological drugs, the biopharma industry is witnessing an increase in the adoption of prefilled syringes.

On Point: Biologics Drive Growth in Pre-Filled Syringes

Jim Walter will take on the role of vice-president of operations for Catalent’s Oral and Specialty Delivery business. 

Catalent Appoints New Vice-President of Operations

The facility will produce parenteral products and delivery devices and is set to create 460 new jobs.

Eli Lilly to Invest $470 Million into New Pharma Manufacturing Facility

CPI has partnered with ImmunoBiology (ImmBio) for the development of a heat-stabilized formulation of a mutli-antigen vaccine candidate against Pneumococcal diseases.

CPI Partners with ImmunoBiology for Heat-Stabilized Formulation of Pneumococcal Vaccine

Lonza and Cryoport have partnered up to strengthen Lonza’s ‘vein-to-vein’ delivery network by removing supply chain hurdles faced by developers of personalized therapeutics.

Lonza, Cryoport Partner in Cell and Gene Therapy Field

On Tuesday, Nov. 5, 2019, Karima Yadi from Becton Dickinson & Co. will present the challenges of using, and necessity for, shorter needles and integrated systems with high viscosity drugs, such as biologics, to improve the patient experience at CPhI Worldwide.

Improving the Patient Experience with High Viscosity/High Volume Drugs

AstraZeneca received approval from FDA for Fasenra Pen, a pre-fillled auto-injector pen that allows for self-administration of its asthma biologic therapy, Fasenra (benralizumab).

FDA Approves AstraZeneca Asthma Drug in Auto-Injector Pen

FDA has approved Novo Nordisk’s Rybelsus (semaglutide), a glucagon-like peptide receptor protein treatment in oral tablet form for type 2 diabetes.

FDA Approves First Oral GLP-1 Treatment for Type 2 Diabetes

The company will supply its heparin sodium injection in prefilled syringe form.